Fasting vs. Non-Fasting Effects on THC to CBD Ratio in the Body
The Significance of THC to CBD Ratio
The ratio of THC to CBD in the body can have crucial therapeutic implications. For instance, higher THC content may result in more psychoactive effects, while higher CBD levels are generally associated with therapeutic outcomes like pain relief and anti-inflammatory effects without psychoactivity. The ratio can be influenced by various factors, including diet, which leads us to the discussion on fasting and non-fasting states (Babalonis et al., 2019).
Fasting vs. Non-Fasting Conditions
Fasting and non-fasting states can impact the pharmacokinetics of cannabinoids, including absorption, distribution, metabolism, and excretion. Research indicates that food can influence the bioavailability of cannabinoids, with fat-rich meals, in particular, amplifying THC concentrations (Taylor et al., 2017). Moreover, CBD absorption is similarly affected by food intake, especially considering its fat-solubility.
Comparison Table: Effects of Formulation and Method of Consumption on Fasting vs. Non-Fasting States
|Method of Consumption||Fasting Effects||Non-Fasting Effects|
|Smoking||Faster absorption, lower bioavailability of THC and CBD||Slower absorption, higher bioavailability of THC and CBD due to a fat-rich meal|
|Oral Capsules||Reduced and inconsistent absorption||Increased absorption, especially when co-ingested with a fat-rich meal|
|Sublingual||Slightly faster absorption, though less impacted by fasting or non-fasting states||Slightly slower absorption, but higher bioavailability if preceded by a meal|
|Edibles||Delayed onset, potentially reduced efficacy||Faster onset and potentially greater efficacy, especially with a fat-rich meal|
- Babalonis, S., et al. (2019). Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.
- Taylor, L., et al. (2017). A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
- Huestis, M. A. (2007). Human Cannabinoid Pharmacokinetics.
Medical Illnesses and Diagnoses of Concern
Individuals with certain conditions such as cardiovascular diseases, liver disorders, and psychological conditions like anxiety disorders and bipolar disorder should exercise caution. For these individuals, the effects of cannabinoids may differ substantially and could interact with their ongoing medications or conditions. Consultation with healthcare professionals like Dr. Caplan at CED Clinic for specialized and guided care is strongly recommended.
📗 Note: If this diagram were a song, it’d be the catchy chorus. For the entire album, tune into “The Doctor-Approved Cannabis Handbook” here 📗